CLINICAL TRIAL OF A BETA‐RECEPTOR BLOCKING AGENT (LB 46) IN MIGRAINE PROPHYLAXIS

Twenty‐four patients were treated with a beta‐blocking agent (Viskén, LB 46 Sandoz) and placebo in double‐blind study. The dosage of Viskén was 15 mg in 11 patients and 7.5 mg in 13 patients, and each remedy was taken for 4 weeks with an interposed 3‐week “wash‐out” period. There was generally no definite change in migraine attack‐frequency or pattern during Viskén medication. Three patients, however, had a remarkably reduced number of attacks on Viskén. This reduction may or may not have been due to Viskén.

[1]  R. Byck,et al.  Monosodium L-Glutamate: Its Pharmacology and Role in the Chinese Restaurant Syndrome , 1969, Science.

[2]  M. Békés,et al.  Treatment of migraine with propranolol. , 1968, Lancet.

[3]  P. Wykes.  The treatment of angina pectoris with coexistent migraine. , 1968, The Practitioner.

[4]  M. Suzman,et al.  The prophylactic value of propranolol in angina pectoris. , 1966, The American journal of cardiology.

[5]  R. Ahlquist,et al.  A study of the adrenotropic receptors. , 1948, The American journal of physiology.

[6]  K. Saameli,et al.  Pharmacological properties of a new beta-receptor blocking agent. , 1970, Triangle; the Sandoz journal of medical science.

[7]  C. Owman,et al.  Adrenergic innervation of the pial circulation. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.